REC-617

Clinical trials for REC-617 explained in plain language.

Never miss a new study

Get alerted when new REC-617 trials appear

Sign up with your email to follow new studies for REC-617, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug takes aim at Hard-to-Treat sarcoma

Disease control Recruiting now

This early-stage trial is testing a new drug called REC-617 in 15 people with a rare type of sarcoma (leiomyosarcoma) that has spread or cannot be removed and has not responded to prior treatments. The drug targets a protein (CDK7) that helps cancer cells grow. The main goal is t…

Matched conditions: REC-617

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Aug 02, 2026 00:00 UTC

REC-617

Get alerted when new REC-617 trials appear

New drug takes aim at Hard-to-Treat sarcoma